Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

We recently published a list of 10 Stocks Skyrocketing Today. In this article, we are going to take a look at where Viking ...

And Novo Nordisk (NYSE: NVO) stock, down 4.9%, is the victim. Where to invest $1,000 right now? Our analyst team just ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...

Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

New York Life Investment Management LLC lessened its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 7.4% during the fourth quarter, according to the company in its most ...